GlassScriptPhysician profile
Deborah M Hall
NPI 1063431823
$436.58
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $103 · 2021: $19.60 · 2022: $16.69.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $151.03 | 2019-2020 | |
| Novo Nordisk INC | $65.15 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $39.28 | 2019-2020 | |
| Amarin Pharma, INC. | $31.10 | 2019 | |
| Sanofi-Aventis U.S. LLC | $26.48 | 2019 | |
| Abbvie INC. | $23.97 | 2019 | |
| Astellas Pharma US INC | $19.04 | 2019 | |
| Lilly USA, LLC | $16.69 | 2022 | |
| Pfizer INC. | $15.70 | 2020 | |
| Merck Sharp & Dohme LLC | $13.07 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $11.91 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.66 | 2019 | |
| Radius Health, INC. | $11.50 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.